J William Harbour

List of Publications by Year in Descending Order

203 papers	13,527 citations	58 h-index	114 g-index
237 ext. papers	15,419 ext. citations	7.2 avg, IF	6.53 L-index

#	Paper	IF	Citations
203	Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma.. *Oncogene*, **2022**,	9.2	2
202	Hematologic Complications Associated With Intra-arterial Chemotherapy for Retinoblastoma Treatment: A Single Institution Experience.. *Journal of Pediatric Hematology/Oncology*, **2022**, 44, 181-185	1.2	0
201	Choroidal Nevus and Melanocytoma **2022**, 7795-7805		
200	Intraocular Lymphoma **2022**, 7783-7793		
199	Functional impact of titin (TTN) mutations in ocular surface squamous neoplasia. *International Journal of Biological Macromolecules*, **2021**, 195, 93-93	7.9	0
198	Therapeutic Escape in GNAQ-mutant Uveal Melanoma: Itch a FAK. *Clinical Cancer Research*, **2021**, 27, 2967-2969	12.9	2
197	Multimodal Imaging in the Diagnosis of Exophytic Juxtapapillary Retinal Capillary Hemangioblastoma. *American Journal of Ophthalmology*, **2021**, 225, 128-136	4.9	1
196	Uphyloplot2: visualizing phylogenetic trees from single-cell RNA-seq data. *BMC Genomics*, **2021**, 22, 419	4.5	4
195	Comprehensive assessment of the effect of eye plaque tilt on tumor dosimetry. *Brachytherapy*, **2021**, 20, 1289-1295	2.4	1
194	Multiple genetically distinct uveal melanomas arise in the same eye of two patients with melanosis oculi. *American Journal of Ophthalmology*, **2021**, 234, 1-5	4.9	
193	RETINOCYTOMA WITH VITREOUS SEEDING: NEW INSIGHTS FROM ENHANCED DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY AND HIGH-RESOLUTION POSTERIOR SEGMENT ULTRASONOGRAPHY. *Retinal Cases and Brief Reports*, **2021**, 15, 68-70	1.1	2
192	Chimerism involving a RB1 pathogenic variant in monochorionic dizygotic twins with twin-twin transfusion syndrome. *American Journal of Medical Genetics, Part A*, **2021**, 185, 208-212	2.5	0
191	Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma. *Molecular Cancer Research*, **2021**, 19, 215-222	6.6	10
190	BAP1 mutant uveal melanoma is stratified by metabolic phenotypes with distinct vulnerability to metabolic inhibitors. *Oncogene*, **2021**, 40, 618-632	9.2	12
189	Choroidal Nevus and Melanocytoma **2021**, 1-11		
188	Kinetic Characterization of ASXL1/2-Mediated Allosteric Regulation of the BAP1 Deubiquitinase. *Molecular Cancer Research*, **2021**, 19, 1099-1112	6.6	
187	Iris Mass in a 14-Month-Old Boy. *JAMA Ophthalmology*, **2021**, 139, 802-803	3.9	

186	Secondary Glaucoma Associated with Intraocular Metastatic Cutaneous Melanoma. *Ophthalmology Glaucoma*, **2021**, 5, 119-119	2.2	
185	Analytical Validation and Performance of a 7-Gene Next-Generation Sequencing Panel in Uveal Melanoma.. *Ocular Oncology and Pathology*, **2021**, 7, 428-436	1.6	0
184	The AMP-dependent kinase pathway is upregulated in BAP1 mutant uveal melanoma. *Pigment Cell and Melanoma Research*, **2021**,	4.5	3
183	Multiregional genetic evolution of metastatic uveal melanoma. *Npj Genomic Medicine*, **2021**, 6, 70	6.2	2
182	Intraocular Lymphoma **2021**, 1-11		
181	Molecular Basis of Uveal Melanoma and Emerging Therapeutic Targets **2021**, 3-12		
180	Global Retinoblastoma Presentation and Analysis by National Income Level. *JAMA Oncology*, **2020**, 6, 685-695	13.4	77
179	Single-cell analysis of olfactory neurogenesis and differentiation in adult humans. *Nature Neuroscience*, **2020**, 23, 323-326	25.5	67
178	Influence of tumor shape and location in eye plaque brachytherapy dosimetry. *Brachytherapy*, **2020**, 19, 249-254	2.4	3
177	Single-cell analysis reveals new evolutionary complexity in uveal melanoma. *Nature Communications*, **2020**, 11, 496	17.4	116
176	Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer. *American Journal of Ophthalmology Case Reports*, **2020**, 18, 100691	1.3	3
175	Decitabine limits escape from MEK inhibition in uveal melanoma. *Pigment Cell and Melanoma Research*, **2020**, 33, 507-514	4.5	13
174	Biological Mechanisms and Clinical Significance of Mutations in Human Cancer. *Cancer Discovery*, **2020**, 10, 1103-1120	24.4	48
173	A novel cardiomyogenic role for Isl1 neural crest cells in the inflow tract. *Science Advances*, **2020**, 6,	14.3	6
172	Impact of Genetic Ancestry on Prognostic Biomarkers in Uveal Melanoma. *Cancers*, **2020**, 12,	6.6	2
171	Vitreoretinal lymphoma followed by systemic diffuse large B cell lymphoma. *Journal of Ophthalmic Inflammation and Infection*, **2019**, 9, 11	2.3	2
170	BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers. *Science Advances*, **2019**, 5, eaax1738	14.3	26
169	Intraocular Metastasis in Unilateral Multifocal Uveal Melanoma Without Melanocytosis or Germline BAP1 Mutations. *JAMA Ophthalmology*, **2019**, 137, 1434-1439	3.9	4

168	Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. *American Journal of Hematology*, **2019**, 94, 455-460	7.1	12
167	Integrative Copy Number Analysis of Uveal Melanoma Reveals Novel Candidate Genes Involved in Tumorigenesis Including a Tumor Suppressor Role for. *Clinical Cancer Research*, **2019**, 25, 5156-5166	12.9	9
166	HDAC Inhibition Enhances the Efficacy of MEK Inhibitor Therapy in Uveal Melanoma. *Clinical Cancer Research*, **2019**, 25, 5686-5701	12.9	42
165	Genomic evolution of uveal melanoma arising in ocular melanocytosis. *Journal of Physical Education and Sports Management*, **2019**, 5,	2.8	6
164	Dosimetric comparison of circular Eye Physics and Collaborative Ocular Melanoma Study plaques to treat uveal melanoma. *Brachytherapy*, **2019**, 18, 404-410	2.4	4
163	BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas. *Clinical Cancer Research*, **2019**, 25, 5663-5673	12.9	24
162	Follow the nevus: the cost-utility of monitoring for growth of choroidal nevi. *International Journal of Ophthalmology*, **2019**, 12, 1456-1464	1.4	1
161	Intraocular Dissemination of Uveal Melanoma Cells Following Radiotherapy: Evolving Management Over the Past Decade. *Ophthalmic Surgery Lasers and Imaging Retina*, **2019**, 50, 573-579	1.4	3
160	Persistent fetal vasculature presenting with axial elongation and platyphakia. *Journal of AAPOS*, **2019**, 23, 51-53	1.3	
159	Are Risk Factors for Growth of Choroidal Nevi Associated With Malignant Transformation? Assessment With a Validated Genomic Biomarker. *American Journal of Ophthalmology*, **2019**, 197, 168-179	4.9	19
158	CD4+/CD8+ immunophenotype switching as a marker for intraocular and CNS involvement in mycosis fungoides. *Leukemia and Lymphoma*, **2019**, 60, 1308-1311	1.9	4
157	ChIPprimersDB: a public repository of verified qPCR primers for chromatin immunoprecipitation (ChIP). *Nucleic Acids Research*, **2019**, 47, D46-D49	20.1	7
156	Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo. *Leukemia*, **2018**, 32, 1834-1837	10.7	12
155	Familial and Somatic Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. *Cancer Research*, **2018**, 78, 1200-1213	10.1	17
154	Punctuated evolution of canonical genomic aberrations in uveal melanoma. *Nature Communications* , **2018**, 9, 116	17.4	106
153	Retinoblastoma With Endophytic and Exophytic Features. *JAMA Ophthalmology*, **2018**, 136, e175064	3.9	1
152	Anterior Chamber Chemotherapy in Retinoblastoma-Necessary But Not Sufficient for Aqueous Seeding Control-Reply. *JAMA Ophthalmology*, **2018**, 136, 597	3.9	1
151	Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma. *American Journal of Ophthalmology*, **2018**, 195, 154-160	4.9	24

150	Congenital Hypertrophy of the Retinal Pigment Epithelium Presenting With Secondary Choroidal Neovascularization. *Ophthalmic Surgery Lasers and Imaging Retina*, **2018**, 49, 276-277	1.4	2
149	Diagnosis of Bilateral Retinocytoma in an Adolescent Patient Using Multimodal Imaging and Genetic Testing. *Ophthalmic Surgery Lasers and Imaging Retina*, **2018**, 49, 812-814	1.4	
148	Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. *Blood*, **2018**, 131, 328-341	2.2	91
147	Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. *Journal of the National Cancer Institute*, **2018**, 110, 1328-1341	9.7	97
146	Drug and disease signature integration identifies synergistic combinations in glioblastoma. *Nature Communications*, **2018**, 9, 5315	17.4	44
145	Prognostic Implications of the Largest Basal Tumor Diameter vs the TNM Staging System in Association With the Gene Expression Profile for Uveal Melanoma-Reply. *JAMA Ophthalmology*, **2017**, 135, 175-176	3.9	3
144	ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis. *Science Advances*, **2017**, 3, e1601602	14.3	25
143	PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. *JAMA Ophthalmology*, **2017**, 135, 541-549	3.9	50
142	Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma. *Ophthalmology*, **2017**, 124, 1532-1539	7.3	20
141	Liquid Biopsy in Retinoblastoma. *JAMA Ophthalmology*, **2017**, 135, 1231	3.9	2
140	Multimodal Imaging of Astrocytic Hamartomas Associated With Tuberous Sclerosis. *Ophthalmic Surgery Lasers and Imaging Retina*, **2017**, 48, 756-758	1.4	4
139	Letter to the Editor: Comparison of Alternative Tumor Size Classifications for Posterior Uveal Melanomas **2017**, 58, 5444		
138	An international survey of classification and treatment choices for group D retinoblastoma. *International Journal of Ophthalmology*, **2017**, 10, 961-967	1.4	20
137	Fluorescein angiography findings in diffuse retinoblastoma: two case reports with clinicopathologic correlation. *Journal of AAPOS*, **2017**, 21, 337-339.e2	1.3	6
136	Molecular Characteristics of Conjunctival Melanoma Using Whole-Exome Sequencing. *JAMA Ophthalmology*, **2017**, 135, 1434-1437	3.9	32
135	Intracameral Topotecan Hydrochloride for Anterior Chamber Seeding of Retinoblastoma. *JAMA Ophthalmology*, **2017**, 135, 1453-1454	3.9	6
134	Preclinical Acute Ocular Safety Study of Combined Intravitreal Carboplatin and Etoposide Phosphate for Retinoblastoma. *Ophthalmic Surgery Lasers and Imaging Retina*, **2017**, 48, 151-159	1.4	7
133	Retinoblastoma: Clinical and Molecular Perspectives **2017**, 355-361		

132	A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature. *Melanoma Research*, **2016**, 26, 481-6	3.3	5
131	ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. *Cancer Cell*, **2016**, 29, 889-904	24.3	86
130	Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. *Oncotarget*, **2016**, 7, 59209-59219	3.3	63
129	PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. *Clinical Cancer Research*, **2016**, 22, 1234-42	12.9	139
128	Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes. *JAMA Ophthalmology*, **2016**, 134, 728-33	3.9	142
127	Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma. *JAMA Ophthalmology*, **2016**, 134, 734-40	3.9	80
126	An Iris Tumor. *JAMA Ophthalmology*, **2016**, 134, 1063-4	3.9	
125	The state of melanoma: challenges and opportunities. *Pigment Cell and Melanoma Research*, **2016**, 29, 404-16	4.5	63
124	Hydroxyapatite versus polyethylene orbital implants for patients undergoing enucleation for uveal melanoma. *Canadian Journal of Ophthalmology*, **2015**, 50, 151-4	1.4	9
123	Epigenetic reprogramming of melanoma cells by vitamin C treatment. *Clinical Epigenetics*, **2015**, 7, 51	7.7	59
122	Molecular Biology of Retinoblastoma. *Essentials in Ophthalmology*, **2015**, 1-13	0.2	
121	Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma. *Investigative Ophthalmology and Visual Science*, **2015**, 56, 1447-58		30
120	Serous macular detachment following a systemic corticosteroid injection. *JAMA Ophthalmology*, **2015**, 133, 473-4	3.9	1
119	EMT-associated factors promote invasive properties of uveal melanoma cells. *Molecular Vision*, **2015**, 21, 919-29	2.3	20
118	Gene expression profiling and regression rate of irradiated uveal melanomas. *Ophthalmic Surgery Lasers and Imaging Retina*, **2015**, 46, 333-7	1.4	9
117	Spectral-Domain Optical Coherence Tomography of Presumed Solitary Circumscribed Retinal Astrocytic Proliferation Versus Astrocytic Hamartoma. *Ophthalmic Surgery Lasers and Imaging Retina*, **2015**, 46, 586-8	1.4	14
116	Retinoblastoma Tumorigenesis **2015**, 61-68		
115	Second Primary Tumors in Retinoblastoma **2015**, 37-41		

114	GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy?. *Cancer Cell*, **2014**, 25, 714-5	24.3	29
113	Prognostic parameters in uveal melanoma and their association with BAP1 expression. *British Journal of Ophthalmology*, **2014**, 98, 1738-43	5.5	87
112	Rapid regression of a subset of class 1 uveal melanomas after Iodine-125 plaque radiotherapy suggests an inflammatory mechanism. *Graefes Archive for Clinical and Experimental Ophthalmology*, **2014**, 252, 2021-2	3.8	4
111	Combined PKC and MEK inhibition for treating metastatic uveal melanoma. *Oncogene*, **2014**, 33, 4722-3	9.2	22
110	Recent developments in prognostic and predictive testing in uveal melanoma. *Current Opinion in Ophthalmology*, **2014**, 25, 234-9	5.1	117
109	Outcomes of iodine-125 plaque brachytherapy for uveal melanoma with intraoperative ultrasonography and supplemental transpupillary thermotherapy. *International Journal of Radiation Oncology Biology Physics*, **2014**, 88, 801-5	4	38
108	A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. *Ophthalmology*, **2014**, 121, 1281-8	7.3	67
107	Distinguishing torpedo maculopathy from similar lesions of the posterior segment. *Ophthalmic Surgery Lasers and Imaging Retina*, **2014**, 45, 222-6	1.4	16
106	A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. *Methods in Molecular Biology*, **2014**, 1102, 427-40	1.4	87
105	Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. *Nature Genetics*, **2013**, 45, 133-5	36.3	342
104	Multimodal imaging of sarcoid choroidal granulomas. *Journal of Ophthalmic Inflammation and Infection*, **2013**, 3, 58	2.3	31
103	BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma. *BMC Cancer*, **2013**, 13, 371	4.8	98
102	Gene expression profiling versus TNM classification. *Ophthalmology*, **2013**, 120, e52-3	7.3	3
101	Gene expressing profiling of iris melanomas. *Ophthalmology*, **2013**, 120, 213, 213.e1-3	7.3	21
100	Patient-derived xenografts recapitulate molecular features of human uveal melanomas. *Molecular Oncology*, **2013**, 7, 625-36	7.9	37
99	Author reply: To PMID 22521086. *Ophthalmology*, **2013**, 120, e51	7.3	4
98	Genomic, prognostic, and cell-signaling advances in uveal melanoma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**, 388-91	7.1	15
97	Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. *Cell Metabolism*, **2013**, 17, 549-61	24.6	167

96	Molecular testing prognostic of low risk in epithelioid uveal melanoma in a child. *British Journal of Ophthalmology*, **2013**, 97, 323-6	5.5	4
95	A role for Jag2 in promoting uveal melanoma dissemination and growth **2013**, 54, 295-306		18
94	Retinoblastoma protein prevents enteric nervous system defects and intestinal pseudo-obstruction. *Journal of Clinical Investigation*, **2013**, 123, 5152-64	15.9	10
93	Genomic, Prognostic, and Cell-Signaling Advances in Uveal Melanoma. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**, 33, 388-391	7.1	18
92	The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma. *PLOS Currents*, **2013**, 5,		51
91	The genetics of uveal melanoma: an emerging framework for targeted therapy. *Pigment Cell and Melanoma Research*, **2012**, 25, 171-81	4.5	132
90	Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. *Ophthalmology*, **2012**, 119, 1596-603	7.3	336
89	Uveal melanoma: molecular pattern, clinical features, and radiation response. *American Journal of Ophthalmology*, **2012**, 154, 227-232.e2	4.9	33
88	High throughput mass spectrometry-based mutation profiling of primary uveal melanoma **2012**, 53, 6991-6		38
87	Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. *Clinical Cancer Research*, **2012**, 18, 408-16	12.9	201
86	Notch signaling promotes growth and invasion in uveal melanoma. *Clinical Cancer Research*, **2012**, 18, 654-65	12.9	54
85	Update in uveal melanoma. *Clinical Advances in Hematology and Oncology*, **2012**, 10, 459-61	0.6	3
84	ABCB1 identifies a subpopulation of uveal melanoma cells with high metastatic propensity. *Pigment Cell and Melanoma Research*, **2011**, 24, 430-7	4.5	21
83	Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. *Retina*, **2011**, 31, 435-40	3.6	64
82	p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independent mechanism that triggers Rb-Hdm2 interaction and apoptosis. *Oncogene*, **2011**, 30, 588-99	9.2	36
81	Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. *Oncologist*, **2011**, 16, 1589-99	5.7	287
80	Loss of Id2 potentiates the tumorigenic effect of Rb inactivation in a mouse model of retinoblastoma. *Current Eye Research*, **2010**, 35, 435-9	2.9	3
79	Review of 676 second primary tumors in patients with retinoblastoma: association between age at onset and tumor type. *JAMA Ophthalmology*, **2010**, 128, 865-70		45

78	An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. *Journal of Molecular Diagnostics*, **2010**, 12, 461-8	5.1	224
77	Frequent mutation of BAP1 in metastasizing uveal melanomas. *Science*, **2010**, 330, 1410-3	33.3	1014
76	Association between gene expression profile, proliferation and metastasis in uveal melanoma. *Current Eye Research*, **2010**, 35, 857-63	2.9	31
75	Id2 deficiency promotes metastasis in a mouse model of ocular cancer. *Clinical and Experimental Metastasis*, **2010**, 27, 91-6	4.7	5
74	Molecular basis of low-penetrance retinoblastoma **2010**, 377-382		
73	Uveal melanoma **2010**, 362-368		
72	Molecular prognostic testing and individualized patient care in uveal melanoma. *American Journal of Ophthalmology*, **2009**, 148, 823-9.e1	4.9	49
71	Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization. *JAMA Ophthalmology*, **2009**, 127, 628-32		30
70	Hepatic arterial chemoembolization for management of metastatic melanoma. *American Journal of Roentgenology*, **2008**, 190, 99-104	5.4	69
69	A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. *Clinical Cancer Research*, **2008**, 14, 3737-45	12.9	83
68	Oncogenic mutations in GNAQ occur early in uveal melanoma **2008**, 49, 5230-4		284
67	Emerging insights into the molecular pathogenesis of uveal melanoma. *Future Oncology*, **2008**, 4, 629-36	3.6	84
66	Integrative genomic analysis of aneuploidy in uveal melanoma. *Clinical Cancer Research*, **2008**, 14, 115-22	12.9	100
65	Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. *Melanoma Research*, **2008**, 18, 184-90	3.3	123
64	Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. *Melanoma Research*, **2008**, 18, 191-200	3.3	99
63	Correlation study of benign cytomorphology and final clinical diagnosis. *Acta Cytologica*, **2008**, 52, 196-200		7
62	Tilting of radioactive plaques after initial accurate placement for treatment of uveal melanoma. *JAMA Ophthalmology*, **2008**, 126, 65-70		33
61	Uveal Melanocytic Tumors **2008**, 225-282		

60	Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. *Clinical Cancer Research*, **2007**, 13, 2923-7	12.9	111
59	Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. *Clinical Cancer Research*, **2007**, 13, 1466-71	12.9	127
58	Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. *Eye*, **2007**, 21, 1198-201	4.4	82
57	Current management of uveal melanoma. *Expert Review of Ophthalmology*, **2007**, 2, 939-946	1.5	19
56	Molecular prognostic testing in uveal melanoma. *Expert Review of Ophthalmology*, **2007**, 2, 65-69	1.5	
55	Molecular prognostic testing in uveal melanoma: has it finally come of age?. *JAMA Ophthalmology*, **2007**, 125, 1122-3		12
54	Cancer genetics **2007**, 31-33		
53	Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. *Cancer Research*, **2006**, 66, 4602-9	10.1	139
52	Prognostic testing in uveal melanoma by transcriptomic profiling of fine needle biopsy specimens. *Journal of Molecular Diagnostics*, **2006**, 8, 567-73	5.1	57
51	Lipid exudation following plaque radiotherapy for posterior uveal melanoma. *American Journal of Ophthalmology*, **2006**, 141, 594-595	4.9	13
50	Eye cancer: unique insights into oncogenesis: the Cogan Lecture. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 1736-45		28
49	Rb at the Interface Between Cell Cycle and Apoptotic Decisions. *Current Molecular Medicine*, **2006**, 6, 713-718	2.5	0
48	Molecular pathobiology of uveal melanoma. *International Ophthalmology Clinics*, **2006**, 46, 167-80	1.7	24
47	Rb at the interface between cell cycle and apoptotic decisions. *Current Molecular Medicine*, **2006**, 6, 713-8	2.5	34
46	DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. *Clinical Cancer Research*, **2005**, 11, 3609-13	12.9	107
45	Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. *American Journal of Ophthalmology*, **2005**, 140, 748-9	4.9	45
44	Fine needle aspiration biopsy with adjunct immunohistochemistry in intraocular tumor management. *Acta Cytologica*, **2005**, 49, 297-308	3	55
43	Uveal melanoma: genetic aspects. *Ophthalmology Clinics of North America*, **2005**, 18, 85-97, viii		36

42	Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. *Investigative Ophthalmology and Visual Science*, **2005**, 46, 1561-4		40
41	MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. *Journal of Cell Biology*, **2005**, 168, 35-40	7.3	201
40	Loss of Rb-E2F repression results in caspase-8-mediated apoptosis through inactivation of focal adhesion kinase. *Journal of Biological Chemistry*, **2005**, 280, 10484-90	5.4	15
39	NBS1 expression as a prognostic marker in uveal melanoma. *Clinical Cancer Research*, **2005**, 11, 1849-53	12.9	53
38	Cytologic diagnosis of intraocular lymphoma in vitreous aspirates. *Acta Cytologica*, **2004**, 48, 487-91	3	46
37	Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. *Cancer Research*, **2004**, 64, 7205-9	10.1	558
36	Association between posterior uveal melanoma and iris freckles, iris naevi, and choroidal naevi. *British Journal of Ophthalmology*, **2004**, 88, 36-8	5.5	21
35	Association between choroidal pigmentation and posterior uveal melanoma in a white population. *British Journal of Ophthalmology*, **2004**, 88, 39-43	5.5	32
34	For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors. *Journal of the National Cancer Institute*, **2004**, 96, 342-3	9.7	26
33	Optical coherence tomography in the evaluation of retinal changes associated with suspicious choroidal melanocytic tumors. *American Journal of Ophthalmology*, **2004**, 137, 90-5	4.9	69
32	Photodynamic therapy for choroidal metastasis from carcinoid tumor. *American Journal of Ophthalmology*, **2004**, 137, 1143-5	4.9	45
31	What is the best treatment for retinoblastoma?. *American Journal of Ophthalmology*, **2004**, 138, 471-3	4.9	9
30	Ocular melanoma: a review and the relationship to cutaneous melanoma. *Archives of Dermatology*, **2003**, 139, 1067-73		72
29	Status of the NF1 tumor suppressor locus in uveal melanoma. *JAMA Ophthalmology*, **2003**, 121, 1311-5		20
28	Pars plana vitrectomy in eyes containing a treated posterior uveal melanoma. *American Journal of Ophthalmology*, **2003**, 136, 471-6	4.9	36
27	Transpupillary thermotherapy versus plaque radiotherapy for suspected choroidal melanomas. *Ophthalmology*, **2003**, 110, 2207-14; discussion 2215	7.3	55
26	Molecular genetics of uveal melanoma. *Current Eye Research*, **2003**, 27, 69-74	2.9	16
25	Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb. *Journal of Biological Chemistry*, **2003**, 278, 19358-66	5.4	45

24	Rate of resolution of exudative retinal detachment after plaque radiotherapy for uveal melanoma. *JAMA Ophthalmology*, **2002**, 120, 1463-9		17
23	Transducible peptide therapy for uveal melanoma and retinoblastoma. *JAMA Ophthalmology*, **2002**, 120, 1341-6		82
22	Photodynamic therapy for circumscribed choroidal hemangioma. *Canadian Journal of Ophthalmology*, **2002**, 37, 314-7	1.4	10
21	Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy. *American Journal of Ophthalmology*, **2002**, 133, 242-8	4.9	20
20	Risk factors for metastasis in retinoblastoma. *Survey of Ophthalmology*, **2002**, 47, 1-16	6.1	152
19	Molecular basis of low-penetrance retinoblastoma. *JAMA Ophthalmology*, **2001**, 119, 1699-704		81
18	The molecular biology of retinoblastoma. *Ocular Immunology and Inflammation*, **2001**, 9, 1-8	2.8	18
17	Rb function in cell-cycle regulation and apoptosis. *Nature Cell Biology*, **2000**, 2, E65-7	23.4	407
16	Chromatin remodeling and Rb activity. *Current Opinion in Cell Biology*, **2000**, 12, 685-9	9	118
15	The Rb/E2F pathway: expanding roles and emerging paradigms. *Genes and Development*, **2000**, 14, 2393-409	12.8	857
14	Deregulation of the Rb and p53 pathways in uveal melanoma. *American Journal of Pathology*, **2000**, 157, 1795-801	5.8	100
13	Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. *Cell*, **2000**, 101, 79-89	56.2	561
12	Tumor suppressor genes in ophthalmology. *Survey of Ophthalmology*, **1999**, 44, 235-46	6.1	8
11	Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. *Cell*, **1999**, 98, 859-69	56.2	819
10	Langerhans cell histiocytosis diagnosed by fine needle biopsy. *JAMA Ophthalmology*, **1997**, 115, 1212-3		6
9	Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma. *Ophthalmology*, **1997**, 104, 1785-92; discussion 1792-3	7.3	66
8	Pars plana vitrectomy in the management of phakic and pseudophakic malignant glaucoma. *JAMA Ophthalmology*, **1996**, 114, 1073-8		71
7	Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. *American Journal of Ophthalmology*, **1996**, 121, 405-13	4.9	260

6	Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma. *Retina*, **1996**, 16, 129-34	3.6	88
5	Initial management and follow-up of melanocytic iris tumors. *Ophthalmology*, **1995**, 102, 1987-93	7.3	46
4	Uveal metastasis from carcinoid tumor. Clinical observations in nine cases. *Ophthalmology*, **1994**, 101, 1084-90	7.3	71
3	Clivus chordoma: a report of 12 recent cases and review of the literature. *Skull Base*, **1991**, 1, 200-6		18
2	Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. *Science*, **1988** , 241, 353-7	33.3	773
1	SparK: A Publication-quality NGS Visualization Tool		6